.STUDY EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to conventional procedure for muscle-invasive sac cancer cells strengthened event-free as well as in general survival, marking a brand new therapy possibility for this health condition.